ADC Therapeutics updates trial strategy, shares react to oncology shift

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 20:05.

ADC Therapeutics SA (CH0498599052) continues to refine its clinical pipeline in blood cancers and solid tumors, following recent updates on its antibody-drug conjugate programs and Nasdaq trading in the U.S. as reported by company filings and market data. ADC Therapeutics investor information

Recent trial updates and regulatory backdrop

ADC Therapeutics SA, listed on Nasdaq in New York, has focused its oncology development on hematologic malignancies such as diffuse large B-cell lymphoma and certain solid tumor indications, with its lead programs involving antibody-drug conjugates targeting specific cell markers per recent company reports. SEC filing overview of ADC Therapeutics

According to the firm’s latest publicly available regulatory filings, ADC Therapeutics has described a portfolio that includes investigational uses of its ADCs in relapsed or refractory lymphoma, while monitoring the competitive landscape with peers such as Seagen and AstraZeneca that also develop oncology-directed antibody-drug conjugates. Reuters coverage of ADC competition in oncology

Biotech sentiment and analyst perspectives

Biotech shares on Nasdaq, including ADC Therapeutics SA, have traded in a volatile pattern in recent weeks as investors weigh clinical trial risk against potential oncology revenues, with sector commentary from houses such as Jefferies and UBS highlighting cautious positioning in smaller-cap drug developers. Jefferies biotech sector note

Analysts tracking antibody-drug conjugate developers note that trial milestones, safety profiles and eventual regulatory decisions drive sentiment more than near-term earnings, and they often compare ADC Therapeutics with established oncology players like Roche, AstraZeneca and Seagen when assessing competitive risks and partnership potential. UBS oncology ADC research

How ADC Therapeutics generates revenue

ADC Therapeutics SA develops and commercializes antibody-drug conjugates for oncology, with its business model centered on research, clinical development and potential product sales or licensing agreements in blood cancers and solid tumors. The company’s revenue prospects depend on trial success, regulatory approvals and collaboration structures with larger pharmaceutical partners.

Trading snapshot for ADC Therapeutics stock

ADC Therapeutics SA shares currently trade on Nasdaq in the United States; recent market data show the stock quoted in U.S. dollars, with intraday moves typical for a clinical-stage biotech as of the latest trading session.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.